Literature DB >> 12611459

Mutagen sensitivity of human lymphoblastoid cells with a BRCA1 mutation.

Kristina Trenz1, Julia Landgraf, Günter Speit.   

Abstract

Previous results indicated that lymphoblastoid cell lines (LCL) with a BRCA1 mutation are hypersensitive to the chromosome-damaging effects of gamma irradiation or hydrogen peroxide as revealed by the micronucleus test. We now investigated six LCL (three with and three without a BRCA1 mutation) in more detail, to see whether LCL represent a useful model for the investigation of mechanisms responsible for the known mutagen sensitivity of lymphocytes from women carrying a BRCA1 mutation. Our results show that there is no systematic difference in radiation sensitivity between LCL with and without a BRCA1 mutation. Spontaneous and gamma radiation-induced micronucleus frequencies were in same range. Furthermore, cytotoxic effects (reduced cell proliferation, reduced viability) induced by gamma radiation were not different. The only difference found was an induction of micronuclei by 10 microM hydrogen peroxide in BRCA1 cell lines while a concentration of 20 microM hydrogen peroxide was necessary to induce micronuclei in control cells. Comet assay experiments did not reveal differences with regard to the induction and removal of primary DNA damage. Furthermore, expression of BRCA1 mRNA after gamma irradiation showed considerable variability and there was no clear difference between cell lines with and without BRCA mutation. These results indicate that LCL with a BRCA1 mutation do not generally show the same mutagen sensitivity as lymphocytes with the same BRCA1 mutation. Therefore, the use of LCL to study the mechanisms underlying mutagen sensitivity due to a heterozygous BRCA1 mutation seems to be limited.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12611459     DOI: 10.1023/a:1022157528247

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.

Authors:  P K Lovelock; S Healey; W Au; E Y M Sum; A Tesoriero; E M Wong; S Hinson; R Brinkworth; A Bekessy; O Diez; L Izatt; E Solomon; M Jenkins; H Renard; J Hopper; P Waring; S V Tavtigian; D Goldgar; G J Lindeman; J E Visvader; F J Couch; B R Henderson; M Southey; G Chenevix-Trench; A B Spurdle; M A Brown
Journal:  J Med Genet       Date:  2005-05-27       Impact factor: 6.318

2.  Evidence that BRCA1- or BRCA2-associated cancers are not inevitable.

Authors:  Bess Levin; Denise Lech; Bernard Friedenson
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

3.  Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.

Authors:  David G Cox; Jacques Simard; Daniel Sinnett; Yosr Hamdi; Penny Soucy; Manon Ouimet; Laure Barjhoux; Carole Verny-Pierre; Lesley McGuffog; Sue Healey; Csilla Szabo; Mark H Greene; Phuong L Mai; Irene L Andrulis; Mads Thomassen; Anne-Marie Gerdes; Maria A Caligo; Eitan Friedman; Yael Laitman; Bella Kaufman; Shani S Paluch; Åke Borg; Per Karlsson; Marie Stenmark Askmalm; Gisela Barbany Bustinza; Katherine L Nathanson; Susan M Domchek; Timothy R Rebbeck; Javier Benítez; Ute Hamann; Matti A Rookus; Ans M W van den Ouweland; Margreet G E M Ausems; Cora M Aalfs; Christi J van Asperen; Peter Devilee; Hans J J P Gille; Susan Peock; Debra Frost; D Gareth Evans; Ros Eeles; Louise Izatt; Julian Adlard; Joan Paterson; Jacqueline Eason; Andrew K Godwin; Marie-Alice Remon; Virginie Moncoutier; Marion Gauthier-Villars; Christine Lasset; Sophie Giraud; Agnès Hardouin; Pascaline Berthet; Hagay Sobol; François Eisinger; Brigitte Bressac de Paillerets; Olivier Caron; Capucine Delnatte; David Goldgar; Alex Miron; Hilmi Ozcelik; Saundra Buys; Melissa C Southey; Mary Beth Terry; Christian F Singer; Anne-Catharina Dressler; Muy-Kheng Tea; Thomas V O Hansen; Oskar Johannsson; Marion Piedmonte; Gustavo C Rodriguez; Jack B Basil; Stephanie Blank; Amanda E Toland; Marco Montagna; Claudine Isaacs; Ignacio Blanco; Simon A Gayther; Kirsten B Moysich; Rita K Schmutzler; Barbara Wappenschmidt; Christoph Engel; Alfons Meindl; Nina Ditsch; Norbert Arnold; Dieter Niederacher; Christian Sutter; Dorothea Gadzicki; Britta Fiebig; Trinidad Caldes; Rachel Laframboise; Heli Nevanlinna; Xiaoqing Chen; Jonathan Beesley; Amanda B Spurdle; Susan L Neuhausen; Yuan C Ding; Fergus J Couch; Xianshu Wang; Paolo Peterlongo; Siranoush Manoukian; Loris Bernard; Paolo Radice; Douglas F Easton; Georgia Chenevix-Trench; Antonis C Antoniou; Dominique Stoppa-Lyonnet; Sylvie Mazoyer; Olga M Sinilnikova
Journal:  Hum Mol Genet       Date:  2011-09-02       Impact factor: 6.150

4.  Controversial BRCA1 allelotypes in commonly used breast cancer cell lines.

Authors:  Sivasundaram Karnan; Morassa Mohseni; Yuko Konishi; Akina Tamaki; Yoshitaka Hosokawa; Ben H Park; Hiroyuki Konishi
Journal:  Breast Cancer Res Treat       Date:  2009-07-08       Impact factor: 4.872

5.  DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers.

Authors:  J Kotsopoulos; Z Chen; K A Vallis; A Poll; P Ainsworth; S A Narod
Journal:  Br J Cancer       Date:  2007-01-15       Impact factor: 7.640

6.  AOP report: Development of an adverse outcome pathway for oxidative DNA damage leading to mutations and chromosomal aberrations.

Authors:  Eunnara Cho; Ashley Allemang; Marc Audebert; Vinita Chauhan; Stephen Dertinger; Giel Hendriks; Mirjam Luijten; Francesco Marchetti; Sheroy Minocherhomji; Stefan Pfuhler; Daniel J Roberts; Kristina Trenz; Carole L Yauk
Journal:  Environ Mol Mutagen       Date:  2022-05-03       Impact factor: 3.579

Review 7.  Lymphoblastoid Cell lines: a Continuous in Vitro Source of Cells to Study Carcinogen Sensitivity and DNA Repair.

Authors:  Tabish Hussain; Rita Mulherkar
Journal:  Int J Mol Cell Med       Date:  2012
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.